As reported in the organization, we are talking about “Ramdesir,” “Hydroxychloroquine,” “Lopinavir/Ritonavir,” and “Interferon.”
Remdesivir, Hydroxychloroquine, Lopinavir/Ritonavir, and Interferon have almost no effect in treating COVID-19 in hospital settings to reduce mortality. This was reported on the night of Thursday to Friday in Geneva by the World Health Organization (WHO).
“Interim results of the Solidarity clinical trial, coordinated by WHO, indicate that the use of Remdesivir, Hydroxychloroquine, and Lopinavir/Ritonavir and Interferon appears to have little or no effect on the reduction rate of mortality after 28 days or a hospital course of treatment for COVID-19 among hospitalized patients,” the WHO stated.
In the Solidarity study, which covers more than 30 countries, experts studied the effect of treatment with these drugs on mortality rates and the length of time patients stay in hospitals.
Earlier, the American pharmaceutical campaign Gilead Sciences claimed that the use of the drug developed by its Remdesivir by patients with coronavirus reduces the recovery period to four days. USA, Japan, Republic of Korea, India, Israel, UK, and Russia approved the use of Remdesivir to treat those infected with the coronavirus. The drug was created as part of testing for the treatment of hepatitis C and respiratory syncytial virus. It was also tested to treat Ebola but was not found to be effective.